ArticleNature communications2019
Distinct CD1d docking strategies exhibited by diverse Type II NKT cell receptors.
Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 31 citations in OpenAlex.
- Liver immunology: Biological role and clinical significance.World journal of hepatology · 2025Review
- Diverse NKT cells regulate early inflammation and neurological outcomes after cardiac arrest and resuscitation.Science translational medicine · 2024Article
- Direct recognition of an intact foreign protein by an αβ T cell receptor.Nature communications · 2024Article
- Lipidomic scanning of self-lipids identifies headless antigens for natural killer T cells.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- A structural perspective of how T cell receptors recognize the CD1 family of lipid antigen-presenting molecules.The Journal of biological chemistry · 2024Review
- Features of the CD1 gene family in rodents and the uniqueness of the immune system of naked mole-rat.Biology direct · 2024Article
- Functional and biological implications of clonotypic diversity among human donor-unrestricted T cells.Immunology and cell biology · 2024Review
- Epigenetic control ofFrontiers in immunology · 2023Article
- Recent Development in NKT-Based Immunotherapy of Glioblastoma: From Bench to Bedside.International journal of molecular sciences · 2022Review
- Multi-Omics Characterizes the Effects and Mechanisms of CD1d in Nonalcoholic Fatty Liver Disease Development.Frontiers in cell and developmental biology · 2022Article
- Benzofuran sulfonates and small self-lipid antigens activate type II NKT cells via CD1d.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- CD1 and MR1 recognition by human γδ T cells.Molecular immunology · 2021Article
- NKT Cells Contribute to the Control of Microbial Infections.Frontiers in cellular and infection microbiology · 2021Review
- Natural killer cells in cancer biology and therapy.Molecular cancer · 2020Review
- MHC Restriction: Where Are We Now?Viral immunology · 2020Article
- α-Glucuronosyl and α-glucosyl diacylglycerides, natural killer T cell-activating lipids from bacteria and fungi.Chemical science · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type I and type II natural killer T (NKT) cells are restricted to the lipid antigen-presenting molecule CD1d. While we have an understanding of the antigen reactivity and function of type I NKT cells, our knowledge of type II NKT cells in health and disease remains unclear. Here we describe a population of type II NKT cells that recognise and respond to the microbial antigen, α-glucuronosyl-diacylglycerol (α-GlcADAG) presented by CD1d, but not the prototypical type I NKT cell agonist, α-galactosylceramide. Surprisingly, the crystal structure of a type II NKT TCR-CD1d-α-GlcADAG complex reveals a CD1d F'-pocket-docking mode that contrasts sharply with the previously determined A'-roof positioning of a sulfatide-reactive type II NKT TCR. Our data also suggest that diverse type II NKT TCRs directed against distinct microbial or mammalian lipid antigens adopt multiple recognition strategies on CD1d, thereby maximising the potential for type II NKT cells to detect different lipid antigens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.